Accurate and rapid antibiotic susceptibility testing using a machine learning-assisted nanomotion technology platform

Autor: Alexander Sturm, Grzegorz Jóźwiak, Marta Pla Verge, Laura Munch, Gino Cathomen, Anthony Vocat, Amanda Luraschi-Eggemann, Clara Orlando, Katja Fromm, Eric Delarze, Michał Świątkowski, Grzegorz Wielgoszewski, Roxana M. Totu, María García-Castillo, Alexandre Delfino, Florian Tagini, Sandor Kasas, Cornelia Lass-Flörl, Ronald Gstir, Rafael Cantón, Gilbert Greub, Danuta Cichocka

Publikováno v: Nature Communications, Vol 15, Iss 1, Pp 1-14 (2024)

Abstract Antimicrobial resistance (AMR) is a major public health threat, reducing treatment options for infected patients. AMR is promoted by a lack of access to rapid antibiotic susceptibility tests (ASTs). Accelerated ASTs can identify effective an

Externí odkaz: https://doaj.org/article/c91862c044384490bccd43ab68863853

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Real-time evaluation of macozinone activity against Mycobacterium tuberculosis through bacterial nanomotion analysis.

Autor: Vocat A; Resistell AG, Muttenz, Switzerland.; Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland., Luraschi-Eggemann A; Resistell AG, Muttenz, Switzerland., Antoni C; Innovative Medicines for Tuberculosis (iM4TB), Lausanne, Switzerland., Cathomen G; Resistell AG, Muttenz, Switzerland., Cichocka D; Resistell AG, Muttenz, Switzerland., Greub G; Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.; Service of Infectious Diseases, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland., Riabova O; Research Centre of Biotechnology RAS, Leninsky Prospect, Moscow, Russia., Makarov V; Research Centre of Biotechnology RAS, Leninsky Prospect, Moscow, Russia., Opota O; Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland., Mendoza A; Innovative Medicines for Tuberculosis (iM4TB), Lausanne, Switzerland., Cole ST; Innovative Medicines for Tuberculosis (iM4TB), Lausanne, Switzerland., Sturm A; Resistell AG, Muttenz, Switzerland.

Publikováno v: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2024 Nov 27, pp. e0131824. Date of Electronic Publication: 2024 Nov 27.